Find important information for patients about once-daily IMBRUVICA®.
Location: Netherlands, North Brabant, Hulten
Investors 1
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
Mentions in press and media 9
| Date | Title | Description |
| 30.12.2025 | Fixed Income Strategies Medicare drug price negotiations may save some retirees more than 50% in 2026, AARP finds | The first 10 prescription drugs subject to Medicare price negotiations go into effect on Jan. 1. Medicare beneficiaries will see substantially lower costs for those treatments in 2026, according to a new AARP report. Enrollees in Medicare P... |
| 12.06.2021 | JOHNSON & JOHNSON Johnson & Johnson : New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression... | GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress Raritan, N.J., June 12, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from... |
| 15.01.2019 | China’s BeiGene gets FDA breakthrough therapy designation for BTK inhibitor | In MCL, the company has a Phase II clinical trial of 86 patients enrolled at 17 sites in China. BeiGene is based in Beijing and has a US headquarters in Cambridge, Massachusetts. Zanubrutinib is a BTK inhibitor, belonging to a class that in... |
| 21.11.2016 | High prices for some leukemia drugs will make them less cost-effective | Pills used to treat a form of leukemia may be more effective and convenient than chemotherapy, but a new study suggests pricing is projected to raise the annual cost of care by 590 percent – to more than $5 billion – over the next decade, s... |
| 25.09.2015 | Former Pharmacyclics CEO raises $75M Series B for new immunotherapy startup Corvus | This new round, ostensibly a Series B, has 33 investors participating. The company has yet to return outreach to discuss the company’s activities, and how it’ll use the funding. OrbiMed Advisors led December’s Series A, though other investo... |
| - | Examining CLL: Personal connection driving treatment research | Chronic lymphocytic leukemia (CLL) accounts for 38% of all leukemia diagnoses.1 Due to CLL’s prominence, the treatment landscape is continuing to evolve with combination therapies and various chemotherapy-free treatment options. To better u... |
| - | Former Pharmacyclics CEO raises $75M Series B for new immunotherapy startup Corvus | Bay area immuno-oncology startup Corvus Pharmaceuticals just raised an impressive $75 million, SEC filings show – just on the heels of a $33 million Series A fundraise this past December. The startup is led by former Pharmacyclics CEO Richa... |
| - | Biomarker test may drive treatment considerations for most common adult leukemia | Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults.1,2 Each year, approximately 20,000 Americans are diagnosed with CLL, with new cases at a rate of 4.9 per 100,000 in adult men and women.3 The estimated five-year surv... |
| - | China’s BeiGene gets FDA breakthrough therapy designation for BTK inhibitor | A Chinese firm has received breakthrough therapy designation from the Food and Drug Administration for a drug it is investigating as a treatment for non-Hodgkin’s lymphomas and slow-growing leukemia. BeiGene said Monday that the FDA had gra... |